<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11615">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955732</url>
  </required_header>
  <id_info>
    <org_study_id>T280/2016</org_study_id>
    <nct_id>NCT02955732</nct_id>
  </id_info>
  <brief_title>Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients</brief_title>
  <acronym>PINDEX</acronym>
  <official_title>Bioavailability and Pharmacokinetics of Intranasal Dexmedetomidine in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to characterize the bioavailability and pharmacokinetics of dexmedetomidine after
      intranasal dosing employing pharmacometric methods in otherwise healthy 1 month to 11 years
      of age children scheduled for minor surgery or other procedures requiring sedation or
      anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability (%) of intranasally given dexmedetomidine</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameter (blood pressure)</measure>
    <time_frame>6 hours</time_frame>
    <description>More than 30% change from the baseline in the blood pressure (measured in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameter (heart rate)</measure>
    <time_frame>6 hours</time_frame>
    <description>More than 30% change from the baseline in the heart rate (measured in beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Procedural Sedation</condition>
  <arm_group>
    <arm_group_label>Intranasal dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 2-4 µg/kg alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.</description>
    <arm_group_label>Intranasal dex</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. The child is scheduled for intra-articular drug injections, hernia repair,
             bronchoscopy or another similar minor procedure or magnetic resonance imaging
             requiring sedation or anesthesia

          -  2. Guardians and patient (if relevant) with fluent skills in the Finnish or Swedish
             language (to understand the given information, to be able to give informed consent
             and communicate with the study personnel).

          -  3. Age between 1 month and 12 years.

          -  4. Normal developmental status including growth (SD -1.5-1.5)

          -  5. Written informed consent from the guardian and the patient (when relevant).

        Exclusion Criteria:

          -  1. A previous history of intolerance to the study drug or to related compounds and
             additives

          -  2. Prior drug therapy with dexmedetomidine in the 14 days prior to the study.

          -  3. Use of any drugs known to cause enzyme induction or inhibition for a period of 30
             days prior to the study, use of any natural products (including grapefruit products)
             for at least 14 days prior to the study and caffeine containing products for at least
             24 hours prior to the study. The use of regular doses of paracetamol is allowed.

          -  4. Existing or recent significant disease that could influence the study outcome or
             cause a health hazard for the subject if he/she would participate in the study.

          -  5. Participation in any other clinical study involving investigational or marketed
             drug products concomitantly or within one month prior to the entry into this study.

          -  6. Clinically significant abnormal findings in physical examination or laboratory
             screening [routine haematology (haemoglobin, haematocrit, red blood cell count, white
             blood cell count, platelets), renal function tests (creatinine, urea) and liver
             function tests (bilirubin)].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panu Uusalo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Anaesthesilogy and Intensive Care, University of Turku and Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riku Aantaa, MD, PhD</last_name>
    <phone>+358 2 3130176</phone>
    <email>riku.aantaa@tyks.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teijo I Saari, MD, PhD</last_name>
    <phone>+358 2 3132967</phone>
    <email>teisaa@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>November 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
